Life

What is the recurrence rate of osteosarcoma?

What is the recurrence rate of osteosarcoma?

Almost one-third of patients with osteosarcoma will experience recurrence of the disease. In these patients, 95% of relapses will occur within 5 years of the initial diagnosis, with an average time to relapse of 1.6 years [1, 7].

Why does osteosarcoma occur in metaphysis?

[3] The process of skeletal remodeling with its associated osteoblastic activity predominate in metaphysis. Hence most osteosarcomas tend to occur in this location. This remodeling is principally seen in adolescents, and interestingly this age group has the peak incidence of osteogenic sarcoma.

How long do dogs live with osteosarcoma?

Without therapy average survival time is approximately two months. This is primarily determined by the discomfort associated with the primary tumour. If amputation is performed the average survival time is increased to six and a half months with 2% of patients alive after two years.

Can you live a long life after osteosarcoma?

Osteosarcoma. Around 40 out of 100 people (around 40%) survive their cancer for 5 years or more after diagnosis.

Can you get osteosarcoma twice?

Osteosarcoma recurrence is possible after a patient completes treatment and is found to be cancer-free for a period of time. A recurrent osteosarcoma can form in the same bone in which the primary cancer originated, or it can affect other tissues and organs, such as the lungs.

Can osteosarcoma come back after surgery?

It may come back locally (near where the first tumor was) or in other parts of the body. Most of the time, if osteosarcoma recurs it will be in the lungs. If possible, surgery to remove the tumor(s) is an important part of treatment, as it offers the best chance for long-term survival.

How do you prevent osteosarcoma recurrence?

Clinical trials have shown that treatment of osteosarcoma with adjuvant chemotherapy improves the patient’s chance of survival and decreases the risk of cancer recurrence compared to local therapy alone. More recently, neoadjuvant chemotherapy has been developed.